Australia Stock Exchange release from RESONANCE HEALTH : R&D Molecular Medicine ASON Project Results of Dosing Study
21/09/2021 06:23
Australia Stock Exchange release from RESONANCE HEALTH RHT.AX : R&D Molecular Medicine ASON Project Results of Dosing Study
Recent news on Resonance Health
See all newsAustralia's Resonance Health jumps on FY26 forecast hike
Brief: Resonance Health Expects FY26 Underlying EBITDA A$2.6 Mln
Brief: Resonance Health Says Martin Blake Retires As Chair
Brief: Resonance Health Contracted For Clinical Drug Trial Worth A$13.775 Mln
Brief: Resonance Seeks Trading Halt Pending Announcement On Execution Of Contract For Services For Clinical Trial By Pharma Co